Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 3/20 | 0.39 |
| ▸ | TACR1 | P25103 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.36 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.36 |
| ▸ | PDE5A | O76074 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25007084 | 0.87 | RIPK1 (0.36) | RORCMEN1KMT2ARIPK1 | |
| SCHEMBL18640948 | 0.87 | RIPK1 (0.40) | TACR1HDAC1HDAC2RIPK1 | |
| SCHEMBL18448056 | 0.86 | RIPK1 (0.49) | RORCRIPK1 | |
| SCHEMBL18640901 | 0.86 | DPP4 (0.37) | RORCPRKCZRIPK1PDE5A | |
| SCHEMBL18640857 | 0.85 | RIPK1 (0.42) | KMT2ARIPK1 | |
| SCHEMBL18640858 | 0.83 | TP53 (0.40) | — | |
| SCHEMBL18640891 | 0.83 | NTRK1 (0.41) | — | |
| SCHEMBL7236411 | 0.79 | HTR7 (0.42) | RORCTACR1MEN1KMT2AHTR7 | |
| SCHEMBL22039428 | 0.79 | HTR7 (0.42) | RORCTACR1MEN1KMT2AHTR7 | |
| SCHEMBL3697218 | 0.75 | DPP4 (0.47) | RORCTACR1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180237441-A1 | Chemical Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2018-08-23 | — | — | US | disclosed |
| EP-3350185-A1 | 1-PHENYLPYRROLIDIN-2-ONE DERIVATIVES AS PERK INHIBITORS | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2018-07-25 | — | — | EP | disclosed |
| WO-2017046737-A1 | 1-PHENYLPYRROLIDIN-2-ONE DERIVATIVES AS PERK INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-03-23 | — | — | WO | disclosed |
| WO-2017046737-A1 | 1-PHENYLPYRROLIDIN-2-ONE DERIVATIVES AS PERK INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180237441-A1 | Chemical Compounds | PSEN1, IRS1, CPT1A | RORC 2101/4885TACR1 679/4885MEN1 1729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.